Another study enrolled 108 patients with advanced stage ovarian cancer, showing that the progression-free survival (PFS) and overall survival (OS) rates were significantly higher in the group with low expression of CD163 (immunostained specimens) in comparison with the high-CD163 expression group [57]. Here, CD163 is linked to ovarian cancer.